Prepaid expenses and other current assets consisted of the following (in thousands):


	March 31, 2025		December 31, 2024
Prepaid clinical trial	$	1,832	$	1,112
Prepaid research and development		926		841
Prepaid insurance		232		249
Deferred offering costs		140		135
Other		536		308
Total prepaid expenses and other current assets	$	3,666	$	2,645

Property, plant and equipment, net consisted of the following (in thousands):


	March 31, 2025			December 31, 2024
Leasehold improvements	$	2,117		$	2,117
Laboratory equipment		3,163			3,130
Computer equipment		674			707
Furniture and fixtures		853			864
Construction in progress		4,247			4,251
		11,054			11,069
Accumulated depreciation		(3,818	)		(3,584	)
Property, plant and equipment, net	$	7,236		$	7,485

Property, plant and equipment, net includes $0.6 million and $0.7 million of assets capitalized as finance leases as of March 31, 2025 and December 31, 2024, respectively.

Depreciation expense was $0.3 million for each of the three months ended March 31, 2025 and 2024, respectively.

Accrued expenses and other current liabilities consisted of the following (in thousands):


	March 31, 2025		December 31, 2024
Accrued compensation	$	2,510	$	5,242
Accrued clinical trial		2,207		1,907
Lease liabilities, current portion		1,808		1,877
Accrued research and development		1,518		1,714
Accrued professional and consulting fees		1,576		725
Warrant liability		336		438
Accrued property, plant and equipment		—		207
Other		806		752
Total accrued expenses and other current liabilities	$	10,761	$	12,862